ZBD(SH:603567) Xin Lang Cai Jing·2025-11-12 02:48Core Viewpoint - The stock of Zhenbaodao has shown a mixed performance in recent trading sessions, with a slight increase on November 12, 2023, and a significant decline in revenue and profit for the first nine months of 2025 compared to the previous year [1][2]. Group 1: Stock Performance - On November 12, Zhenbaodao's stock rose by 2.16%, reaching a price of 11.85 CNY per share, with a trading volume of 48.31 million CNY and a turnover rate of 0.44%, resulting in a total market capitalization of 11.15 billion CNY [1]. - Year-to-date, Zhenbaodao's stock price has increased by 3.49%, while it has seen a 3.40% rise over the last five trading days, a 1.90% decline over the last 20 days, and a 6.40% drop over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on October 27, where it recorded a net buy of -4.88 million CNY [1]. Group 2: Financial Performance - For the period from January to September 2025, Zhenbaodao reported a revenue of 919 million CNY, reflecting a year-on-year decrease of 54.73%, and a net profit attributable to shareholders of -373 million CNY, a decline of 193.81% compared to the previous year [2]. - Cumulatively, since its A-share listing, Zhenbaodao has distributed a total of 1.302 billion CNY in dividends, with 356 million CNY distributed over the past three years [3]. Group 3: Company Overview - Zhenbaodao Pharmaceutical Co., Ltd. is located in Harbin, Heilongjiang Province, and was established on October 28, 1996, with its shares listed on April 24, 2015. The company specializes in the research, production, and sales of traditional Chinese medicine, focusing on high-end formulations [1]. - The company's main revenue sources include sales of proprietary medicines (84.82%), purchased medicinal materials (7.13%), purchased pharmaceuticals (5.11%), and other income sources [1].